Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The spike-protein component of ACM-001 is modeled after the immune-evasive beta variant. In animal studies the clinical vaccine candidate was safe and generated a protective immune response against the beta-variant and ancestral form of SARS-2.
Product Name : ACM-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2022
Lead Product(s) : Pindolol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Temasek-backed Tychan to Start Human Trials Next Week for COVID-19 Treatment
Details : The study to be conducted by Tychan is meant to determine the safety and effectiveness of TY027, a monoclonal antibody or immune system protein that specifically targets Sars-CoV-2, the virus that causes Covid-19.
Product Name : TY027
Product Type : Antibody
Upfront Cash : Inapplicable
October 06, 2020
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TY014
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NEJM Study Demonstrates Safety and Efficacy of mAb to Treat Yellow Fever
Details : Data published in the New England Journal of Medicine demonstrate that TY014 was not only safe and well tolerated at the highest doses tested, but also completely eradicated the yellow fever virus in the bloodstream of all participants within 48 hours of...
Product Name : TY014
Product Type : Antibody
Upfront Cash : Inapplicable
July 30, 2020
Lead Product(s) : TY014
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable